RxDoctor Payments Data

Dominique Taylor, MD

Internal Medicine · Las Vegas, NVNPI 1487053716

Payments from drug & device makers

$976in general payments, 2019–2025

Across 52 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$178
  • Novo Nordisk$119
  • Lilly USA, LLC$87
  • Boehringer Ingelheim$79
  • Novartis$61
  • Scilex Pharmaceuticals Inc.$57
  • plus $396 from 17 others

What the payments were for

  • Food & beverage$976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$976 in reported general payments places this provider in the 70th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$18,204
Medicare patients
55
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$116,951
JardianceEmpagliflozin80$106,356
EliquisApixaban79$101,730
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,518
SymbicortBudesonide/Formoterol Fumarate25$9,550
Atorvastatin Calcium816$7,361
Epinephrine11$6,962
Breo ElliptaFluticasone/Vilanterol13$6,130
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,766
Albuterol Sulfate HfaAlbuterol Sulfate166$5,430
Omeprazole236$4,725
Gabapentin223$4,262
Fluticasone Propionate171$2,973
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$2,875
Losartan Potassium374$2,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$87$116,95191 claims
Boehringer IngelheimJardiance$79$106,35680 claims
PfizerEliquis$35$101,73079 claims
AstraZenecaSymbicort$12$9,55025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →